Tenaya Therapeutics, Inc (TNYA) Fair Value & Analysis

Healthcare · US · Market cap $158M

Below-average quality, and screening another 56% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($0.3995). The favourable scenario is already priced in.
• Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($0.2125 to $0.3995) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

60‑month range $0.3879 – $29.58 · fair‑value band $0.2125 – $0.3995 · the $0.7268 price screens above the $0.3230 fair value. Dashed = 300-day average. As of Jul 24, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Tenaya Therapeutics, Inc (TNYA) currently trades at $0.7268, while our model-based Fair Value estimate is $0.3230, implying the stock looks roughly 55.6% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Trailing-twelve-month revenue stands at $225K. It earns a return on equity of -73.6%. The balance sheet holds a net cash position of $89.7M. Fundamentals as of Jul 24, 2026

Our scenario range runs from $0.2125 (bear case) to $0.3995 (bull case); at $0.7268, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 69% below its 52-week high and 37% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -56%, TNYA screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Full company description

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Tenaya Therapeutics, Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$90.6M in FY2025.

TNYA screens 56% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

• Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire · Jul 15, 2026
• Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement Nasdaq · Jun 30, 2026
• Tenaya Therapeutics Appoints Eric Hyllengren As CFO Nasdaq · Jun 29, 2026
• Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer GlobeNewswire · Jun 29, 2026

Peer Group

Biotechnology · 601 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 24, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.